30.14
Precedente Chiudi:
$29.10
Aprire:
$29.26
Volume 24 ore:
532.57K
Relative Volume:
3.41
Capitalizzazione di mercato:
$498.45M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-9.882
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
+14.25%
1M Prestazione:
+166.73%
6M Prestazione:
+239.41%
1 anno Prestazione:
+89.32%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Confronta RAPT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RAPT
Rapt Therapeutics Inc
|
30.14 | 481.25M | 3.25M | -116.80M | -98.17M | -3.05 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-09-26 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2025-07-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
2025-05-22 | Ripresa | H.C. Wainwright | Buy |
2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2024-11-13 | Downgrade | Stifel | Buy → Hold |
2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
2024-02-22 | Downgrade | UBS | Buy → Neutral |
2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2024-02-16 | Iniziato | Evercore ISI | Outperform |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2023-09-14 | Iniziato | Berenberg | Buy |
2023-08-09 | Iniziato | Stifel | Buy |
2023-06-15 | Iniziato | Barclays | Overweight |
2023-01-04 | Iniziato | Guggenheim | Buy |
2022-12-01 | Iniziato | Goldman | Buy |
2022-09-21 | Iniziato | CapitalOne | Overweight |
2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
2021-12-09 | Iniziato | JP Morgan | Overweight |
2021-08-12 | Iniziato | SVB Leerink | Outperform |
2021-06-21 | Iniziato | Piper Sandler | Overweight |
2020-06-01 | Iniziato | H.C. Wainwright | Buy |
2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
2020-04-13 | Iniziato | ROTH Capital | Buy |
2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
2019-11-25 | Iniziato | UBS | Buy |
2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
Why RAPT Therapeutics Inc. stock is seen as undervaluedQuarterly Investment Review & Free Reliable Trade Execution Plans - newser.com
How analysts rate RAPT Therapeutics Inc. stock today2025 Investor Takeaways & Risk Managed Trade Strategies - newser.com
Why RAPT Therapeutics Inc. (0RA0) stock stays on top picksWeekly Gains Report & Free Daily Entry Point Trade Alerts - newser.com
Is RAPT Therapeutics Inc. (0RA) stock bottoming after sell offQuarterly Profit Summary & High Conviction Buy Zone Picks - newser.com
How RAPT Therapeutics Inc. (0RA) stock performs in volatility spikesJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Will RAPT Therapeutics Inc. stock maintain growth story2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
Can swing trading help recover from RAPT Therapeutics Inc. lossesJuly 2025 Fed Impact & Community Consensus Picks - newser.com
How to use a screener to detect RAPT Therapeutics Inc. breakoutsFed Meeting & Comprehensive Market Scan Reports - newser.com
Published on: 2025-10-02 21:38:33 - newser.com
Will RAPT Therapeutics Inc. (0RA) stock draw ESG focused fundsRisk Management & Daily Profit Focused Screening - newser.com
Clear Street Maintains RAPT Therapeutics (RAPT) Buy Recommendation - Nasdaq
Published on: 2025-09-30 02:47:57 - newser.com
Rapt Therapeutics stock price target raised to $41 from $24 at Clear Street - Investing.com Canada
What hedge fund moves indicate for RAPT Therapeutics Inc. (0RA) stockJuly 2025 Macro Moves & Weekly Consistent Profit Watchlists - newser.com
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock rises after FDA clears IND for food allergy trial - Investing.com Nigeria
RAPT Therapeutics Announces FDA Clearance of IND - GlobeNewswire
Rapt Therapeutics announces FDA clearance to proceed to phase 2b trial of RPT904 in food allergy - MarketScreener
RAPT Therapeutics' Food Allergy Drug Gets FDA Clearance for Phase 2b Trial - MarketScreener
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy - The Manila Times
RAPT Therapeutics Announces FDA Clearance for IND Application to Initiate Phase 2b Trial of RPT904 in Food Allergy Treatment - Quiver Quantitative
How to build a dashboard for RAPT Therapeutics Inc. stockJuly 2025 Sector Moves & AI Driven Stock Movement Reports - newser.com
FDA Green Light: RAPT Therapeutics' Novel Food Allergy Treatment Heads to Critical Phase 2b Trial - Stock Titan
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):